{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:56:22Z","timestamp":1792090582048,"version":"4.4.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009169","name":"Assiut University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009169","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) affects children and is increasingly prevalent alongside rising childhood obesity. The MASLD spectrum spans from simple hepatic steatosis to metabolic-associated steatohepatitis (MASH), fibrosis, and cirrhosis. Despite this rising prevalence, the optimal pharmacotherapy for pediatric MASLD remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This systematic review and network meta-analysis aimed to evaluate the efficacy of different pharmacotherapies in managing pediatric MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Included in this meta-analysis were randomized controlled trials. The diagnosis of MASLD was established using medical imaging techniques such as ultrasonography or magnetic resonance imaging, or via liver biopsy, provided that patients had no other chronic liver diseases or secondary causes of liver steatosis. A systematic search of five electronic databases was conducted up to August 2024. Data were synthesized using a random-effects model, with results expressed as pooled mean differences (MDs) for continuous outcomes or relative risks (RRs) for categorical outcomes, each with a 95% confidence interval (CI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This analysis included 26 trials involving 1503 patients. The mean age of patients across studies ranged from 7.41 to 14.06 years. Vitamin D demonstrated the best ranking in managing MASLD, significantly reducing NAFLD Activity Score (NAS) and improving lipid profiles by reducing low-density lipoprotein (LDL) and total cholesterol, while increasing high-density lipoprotein (HDL) levels. Besides, vitamin D combined with docosahexaenoic acid (DHA) showed the strongest effect in reducing triglycerides. Vitamin E was associated with more patients achieving nonalcoholic steatohepatitis (NASH) resolution. Regarding liver transaminases, Cysteamine Bitartrate Delayed Release (CBDR) most effectively reduced ALT levels, AST levels, and fibrosis score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our NMA suggests pharmacotherapy holds promise for pediatric MASLD, with vitamin D and vitamin E presenting the most consistent benefits across histologic and laboratory outcomes. Future well-designed RCTs integrating standardized MASLD diagnosis and lifestyle interventions are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-025-04393-x","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T07:20:12Z","timestamp":1765178412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of pharmacotherapies on pediatric patients with metabolic dysfunction-associated steatotic liver disease: a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-6874-3393","authenticated-orcid":false,"given":"Shehab","family":"Yaser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Yaser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazem E.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Khalafalla","family":"Darwish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed E.","family":"Haseeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas Hussein","family":"Heiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Mabrouk","family":"Ghonaim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Aboeldahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyad","family":"Bady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"4393_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-024-02434-5","volume":"23","author":"H Zheng","year":"2024","unstructured":"Zheng H, Sechi LA, Navarese EP, Casu G, Vidili G. Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review. Cardiovasc Diabetol. 2024;23:346.","journal-title":"Cardiovasc Diabetol"},{"key":"4393_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140908","volume":"10","author":"EL Anderson","year":"2015","unstructured":"Anderson EL, Howe LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015;10:e0140908.","journal-title":"PLoS One"},{"key":"4393_CR3","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1542\/peds.2006-1212","volume":"118","author":"JB Schwimmer","year":"2006","unstructured":"Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388\u201393.","journal-title":"Pediatrics"},{"key":"4393_CR4","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/apt.17096","volume":"56","author":"J Li","year":"2022","unstructured":"Li J, Ha A, Rui F, Zou B, Yang H, Xue Q, et al. Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000\u20132021. Aliment Pharmacol Ther. 2022;56:396\u2013406.","journal-title":"Aliment Pharmacol Ther"},{"key":"4393_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/cld.1027","volume":"17","author":"EL Yu","year":"2021","unstructured":"Yu EL, Schwimmer JB. Epidemiology of pediatric nonalcoholic fatty liver disease. Clin Liver Dis. 2021;17:196\u20139.","journal-title":"Clin Liver Dis"},{"key":"4393_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2016.1971","volume":"170","author":"KP Newton","year":"2016","unstructured":"Newton KP, Hou J, Crimmins NA, Lavine JE, Barlow SE, Xanthakos SA, et al. Prevalence of prediabetes and type 2 diabetes in children with nonalcoholic fatty liver disease. JAMA Pediatr. 2016;170:e161971.","journal-title":"JAMA Pediatr"},{"key":"4393_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases. Hepatology. 2018;67:328\u201357.","journal-title":"Hepatology"},{"issue":"5","key":"4393_CR8","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10620-016-4126-1","volume":"61","author":"JA Africa","year":"2016","unstructured":"Africa JA, Newton KP, Schwimmer JB. Lifestyle interventions including nutrition, exercise, and supplements for nonalcoholic fatty liver disease in children. Dig Dis Sci. 2016;61(5):1375\u201386.","journal-title":"Dig Dis Sci"},{"key":"4393_CR9","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1001\/jama.2011.520","volume":"305","author":"JE Lavine","year":"2011","unstructured":"Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or Metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659\u201368.","journal-title":"JAMA"},{"key":"4393_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00431-021-04243-4","volume":"181","author":"D El Amrousy","year":"2022","unstructured":"El Amrousy D, Abdelhai D, Shawky D. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial. Eur J Pediatr. 2022;181:579\u201386.","journal-title":"Eur J Pediatr"},{"key":"4393_CR11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/jpn3.12312","volume":"79","author":"P Babu Balagopal","year":"2024","unstructured":"Babu Balagopal P, Kohli R, Uppal V, Averill L, Shah C, McGoogan K, et al. Effect of N-acetyl cysteine in children with metabolic dysfunction-associated steatotic liver disease-a pilot study. J Pediatr Gastroenterol Nutr. 2024;79:652\u201360.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4393_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4274\/jcrpe.1749","volume":"7","author":"M Boyraz","year":"2015","unstructured":"Boyraz M, Pirgon \u00d6, D\u00fcndar B, \u00c7ekmez F, Hatipo\u011flu N. Long-term treatment with n-3 polyunsaturated fatty acids as a monotherapy in children with nonalcoholic fatty liver disease. J Clin Res Pediatr Endocrinol. 2015;7:121\u20137.","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"4393_CR13","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00431-023-05369-3","volume":"183","author":"A Zahmatkesh","year":"2024","unstructured":"Zahmatkesh A, Sohouli MH, Shojaie S, Rohani P. The effect of Orlistat in the treatment of non-alcoholic fatty liver in adolescents with overweight and obese. Eur J Pediatr. 2024;183:1173\u201382.","journal-title":"Eur J Pediatr"},{"key":"4393_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"MB Vos","year":"2017","unstructured":"Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R. Naspghan clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr. 2017;64:319\u201334.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4393_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","volume":"162","author":"B Hutton","year":"2015","unstructured":"Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777\u201384.","journal-title":"Ann Intern Med"},{"key":"4393_CR16","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1136\/bmj.38636.593461.68","volume":"331","author":"T Greenhalgh","year":"2005","unstructured":"Greenhalgh T, Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ. 2005;331:1064\u20135.","journal-title":"BMJ"},{"key":"4393_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A. Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol. 2024;24:243.","journal-title":"BMC Med Res Methodol"},{"key":"4393_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"4393_CR19","doi-asserted-by":"crossref","unstructured":"Balduzzi S, R\u00fccker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O et al. Netmeta: an R package for network Meta-Analysis using frequentist methods. J Stat Softw. 2023;106.","DOI":"10.18637\/jss.v106.i02"},{"key":"4393_CR20","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/jrsm.1373","volume":"10","author":"RK Owen","year":"2019","unstructured":"Owen RK, Bradbury N, Xin Y, Cooper N, Sutton A, MetaInsight. An interactive web-based tool for analyzing, interrogating, and visualizing network meta-analyses using R-shiny and Netmeta. Res Synth Methods. 2019;10:569\u201381.","journal-title":"Res Synth Methods"},{"key":"4393_CR21","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1024\/0300-9831\/a000086","volume":"81","author":"M Akcam","year":"2011","unstructured":"Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, Dundar BN. Therapeutic effect of Metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. Int J Vitam Nutr Res. 2011;81:398\u2013406.","journal-title":"Int J Vitam Nutr Res"},{"key":"4393_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-024-04993-8","volume":"24","author":"FDR Al-Baiaty","year":"2024","unstructured":"Al-Baiaty FDR, Ishak S, Mohd Zaki F, Masra F, Abdul Aziz DA, Wan Md Zin WN, et al. Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial. BMC Pediatr. 2024;24:529.","journal-title":"BMC Pediatr"},{"key":"4393_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168216","volume":"11","author":"C Della Corte","year":"2016","unstructured":"Della Corte C, Carpino G, De Vito R, De Stefanis C, Alisi A, Cianfarani S, et al. Docosahexanoic acid plus vitamin D treatment improves features of NAFLD in children with serum vitamin D deficiency: results from a single centre trial. PLoS One. 2016;11:e0168216.","journal-title":"PLoS One"},{"key":"4393_CR24","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17795\/compreped-6249","volume":"4","author":"R Ghergherehchi","year":"2012","unstructured":"Ghergherehchi R, Hazhir N, Mostafa Gharehbaghi M. Lifestyle intervention and vitamin E therapy in obese children with nonalcoholic fatty liver disease. J Compr Ped. 2012;4:62\u20135.","journal-title":"J Compr Ped"},{"key":"4393_CR25","doi-asserted-by":"crossref","unstructured":"Homaei A, Alhadad M, Arad B, Saffari F. Effect of Metformin or vitamin E on ultrasonographic grade and biochemical findings of children and adolescents with nonalcoholic fatty liver disease: A randomized clinical trial. J Compr Ped. 2022;13.","DOI":"10.5812\/compreped-123944"},{"key":"4393_CR26","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1016\/j.jpeds.2015.01.056","volume":"166","author":"W Janczyk","year":"2015","unstructured":"Janczyk W, Lebensztejn D, Wierzbicka-Ruci\u0144ska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al. Omega-3 fatty acids therapy in children with nonalcoholic fatty liver disease: a randomized controlled trial. J Pediatr. 2015;166:1358\u201363. e1.","journal-title":"J Pediatr"},{"key":"4393_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1053\/j.gastro.2016.08.027","volume":"151","author":"JB Schwimmer","year":"2016","unstructured":"Schwimmer JB, Lavine JE, Wilson LA, Neuschwander-Tetri BA, Xanthakos SA, Kohli R, et al. In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores. Gastroenterology. 2016;151:1141\u2013e11549.","journal-title":"Gastroenterology"},{"key":"4393_CR28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/j.numecd.2012.10.010","volume":"23","author":"V Nobili","year":"2013","unstructured":"Nobili V, Alisi A, Della Corte C, Ris\u00e9 P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutr Metab Cardiovasc Dis. 2013;23:1066\u201370.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"4393_CR29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/hep.22336","volume":"48","author":"V Nobili","year":"2008","unstructured":"Nobili V, Manco M, Devito R, Di Ciommo V, Comparcola D, Sartorelli MR, et al. Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial. Hepatology. 2008;48:119\u201328.","journal-title":"Hepatology"},{"issue":"2","key":"4393_CR30","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1089\/ars.2018.7704","volume":"31","author":"V Nobili","year":"2019","unstructured":"Nobili V, Alisi A, Mosca A, Crudele A, Zaffina S, Denaro M, et al. The antioxidant effects of Hydroxytyrosol and vitamin E on pediatric nonalcoholic fatty liver disease, in a clinical trial: A new treatment? Antioxid Redox Signal. 2019;31(2):127\u201333.","journal-title":"Antioxid Redox Signal"},{"key":"4393_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1399-5448.2008.00450.x","volume":"10","author":"KJ Nadeau","year":"2009","unstructured":"Nadeau KJ, Ehlers LB, Zeitler PS, Love-Osborne K. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents. Pediatr Diabetes. 2009;10:5\u201313.","journal-title":"Pediatr Diabetes"},{"key":"4393_CR32","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1007\/s12011-023-03954-z","volume":"202","author":"V Ostadmohammadi","year":"2024","unstructured":"Ostadmohammadi V, Namazi MJ, Rezasoltani M, Kheirkhah D, Rajabi M, Sharif A, et al. Effects of zinc supplementation on inflammatory status and nonalcoholic steatohepatitis in overweight or obese children: a randomized clinical trial. Biol Trace Elem Res. 2024;202:3496\u2013503.","journal-title":"Biol Trace Elem Res"},{"key":"4393_CR33","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.numecd.2015.04.003","volume":"25","author":"L Pacifico","year":"2015","unstructured":"Pacifico L, Bonci E, Di Martino M, Versacci P, Andreoli G, Silvestri LM, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2015;25:734\u201341.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"4393_CR34","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1515\/jpem-2020-0642","volume":"34","author":"H Saneian","year":"2021","unstructured":"Saneian H, Khalilian L, Heidari-Beni M, Khademian M, Famouri F, Nasri P, et al. Effect of l-carnitine supplementation on children and adolescents with nonalcoholic fatty liver disease (NAFLD): a randomized, triple-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2021;34:897\u2013904.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"4393_CR35","doi-asserted-by":"crossref","unstructured":"Tock L, D\u00e2maso AR, de Piano A, Carnier J, Sanches PL, Lederman HM et al. Long-term effects of metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents. J Obes. 2010;2010.","DOI":"10.1155\/2010\/831901"},{"key":"4393_CR36","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/gastroent15020024","volume":"15","author":"VI Tovar-Villegas","year":"2024","unstructured":"Tovar-Villegas VI, Kang Y, Ibarra-Reynoso L, del R, Olvera-Ju\u00e1rez M, Gomez-Ojeda A, Bosquez-Mendoza VM, et al. Oral L-Citrulline supplementation improves fatty liver and dyslipidemia in adolescents with abdominal obesity: A Parallel, Double-Blind, randomized clinical trial. Gastroenterol Insights. 2024;15:354\u201365.","journal-title":"Gastroenterol Insights"},{"key":"4393_CR37","first-page":"48","volume":"38","author":"P Vajro","year":"2004","unstructured":"Vajro P, Mandato C, Franzese A, Ciccimarra E, Lucariello S, Savoia M, et al. Vitamin E treatment in pediatric obesity-related liver disease: a randomized study. J Pediatr Gastroenterol Nutr. 2004;38:48\u201355.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4393_CR38","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/hep.32403","volume":"76","author":"MB Vos","year":"2022","unstructured":"Vos MB, Van Natta ML, Blondet NM, Dasarathy S, Fishbein M, Hertel P, et al. Randomized placebo-controlled trial of Losartan for pediatric NAFLD. Hepatology. 2022;76:429\u201344.","journal-title":"Hepatology"},{"key":"4393_CR39","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.3748\/wjg.14.1598","volume":"14","author":"C-L Wang","year":"2008","unstructured":"Wang C-L, Liang L, Fu J-F, Zou C-C, Hong F, Xue J-Z, et al. Effect of lifestyle intervention on non-alcoholic fatty liver disease in Chinese obese children. World J Gastroenterol. 2008;14:1598\u2013602.","journal-title":"World J Gastroenterol"},{"key":"4393_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-00967-y","volume":"22","author":"J Xue","year":"2022","unstructured":"Xue J, Liang S, Ma J, Xiao Y. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. BMC Endocr Disord. 2022;22:49.","journal-title":"BMC Endocr Disord"},{"key":"4393_CR41","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1139\/apnm-2016-0689","volume":"42","author":"E Z\u00f6hrer","year":"2017","unstructured":"Z\u00f6hrer E, Alisi A, Jahnel J, Mosca A, Della Corte C, Crudele A, et al. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial. Appl Physiol Nutr Metab. 2017;42:948\u201354.","journal-title":"Appl Physiol Nutr Metab"},{"key":"4393_CR42","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1002\/hep.23724","volume":"51","author":"M Manco","year":"2010","unstructured":"Manco M, Ciampalini P, Nobili V. Low levels of 25-hydroxyvitamin D(3) in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology. 2010;51:2229. author reply 2230.","journal-title":"Hepatology"},{"key":"4393_CR43","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1080\/00365521.2018.1501091","volume":"53","author":"A Geier","year":"2018","unstructured":"Geier A, Eichinger M, Stirnimann G, Semela D, Tay F, Seifert B, et al. Treatment of non-alcoholic steatohepatitis patients with vitamin D: a double-blinded, randomized, placebo-controlled pilot study. Scand J Gastroenterol. 2018;53:1114\u201320.","journal-title":"Scand J Gastroenterol"},{"key":"4393_CR44","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.3945\/jn.117.254292","volume":"147","author":"J Dasarathy","year":"2017","unstructured":"Dasarathy J, Varghese R, Feldman A, Khiyami A, McCullough AJ, Dasarathy S. Patients with nonalcoholic fatty liver disease have a low response rate to vitamin D supplementation. J Nutr. 2017;147:1938\u201346.","journal-title":"J Nutr"},{"key":"4393_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0638-y","volume":"14","author":"I Barchetta","year":"2016","unstructured":"Barchetta I, Del Ben M, Angelico F, Di Martino M, Fraioli A, La Torre G, et al. No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med. 2016;14:92.","journal-title":"BMC Med"},{"key":"4393_CR46","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1136\/gutjnl-2015-310417","volume":"65","author":"MT Kitson","year":"2016","unstructured":"Kitson MT, Pham A, Gordon A, Kemp W, Roberts SK. High-dose vitamin D supplementation and liver histology in NASH. Gut. 2016;65:717\u20138.","journal-title":"Gut"},{"key":"4393_CR47","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/hep.30368","volume":"71","author":"E Vilar-Gomez","year":"2020","unstructured":"Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020;71:495\u2013509.","journal-title":"Hepatology"},{"key":"4393_CR48","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","volume":"92","author":"SA Polyzos","year":"2019","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397.","journal-title":"Metabolism"},{"key":"4393_CR49","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1007\/s12020-024-03783-7","volume":"85","author":"A Serbis","year":"2024","unstructured":"Serbis A, Polyzos SA, Paschou SA, Siomou E, Kiortsis DN. Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children? Endocrine. 2024;85:988\u20131006.","journal-title":"Endocrine"},{"key":"4393_CR50","unstructured":"https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash. Accessed 5 Oct 2025."},{"key":"4393_CR51","unstructured":"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease. Accessed 5 Oct 2025."},{"key":"4393_CR52","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/jpepsy\/jsw054","volume":"42","author":"MB McCullough","year":"2017","unstructured":"McCullough MB, Janicke D, Odar Stough C, Robson S, Bolling C, Zion C, et al. Barriers to recruitment in pediatric obesity trials: comparing opt-in and opt-out recruitment approaches. J Pediatr Psychol. 2017;42:174\u201385.","journal-title":"J Pediatr Psychol"},{"key":"4393_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108294","volume":"240","author":"X Theodoridis","year":"2022","unstructured":"Theodoridis X, Kalopitas G, Vadarlis A, Bakaloudi DR, Gkiourtzis \u039d, Dionysopoulos G, et al. Comparative efficacy of different treatment modalities in the management of pediatric non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Pharmacol Ther. 2022;240:108294.","journal-title":"Pharmacol Ther"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04393-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-04393-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-04393-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T09:02:21Z","timestamp":1765184541000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-04393-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4393"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-04393-x","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"853"}}